Week 26 in the war on cancer. It has been half a year since we started regarding this fight as a war. A war that we are determined to win.
Here are the highlights of the past week:
-Dyanne started Tagrisso (aka AZD9291 aka osimertinib) on Monday this week. The drug is tailormade for patients who have taken erlotinib and then gotten resistant to erlotinib due to a mutation called T790M. The drug is a so-called "targeted therapy", meaning that it targets this specific mutation. Studies done show that it gives patients with brain metastasis a median progress free survival (PFS) of 8 months. We got half the median PFS on erlotinib, but hope to be luckier this time.